We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 16

USPTO Says Overlapping Range In Prior Art Insufficient to Invalidate Method of Treatment Patent
  • Dechert LLP
  • USA
  • April 13 2018

Pharmaceutical patents frequently claim treatment methods that utilize a range of amounts or concentrations for the active ingredient or excipients

Can a Defendant NHS Trust withdraw from admissions formalised in a consent order? Yes, according to Kelly Marie Simmons v City Hospitals Sunderland NHS Foundation Trust
  • 1 Chancery Lane
  • United Kingdom
  • October 21 2016

The recent High Court decision of Kelly Marie Simmons v City Hospitals Sunderland NHS Foundation Trust (2016) is worthy of note for those practising

Claims are construed in ANDA case - March, 2016
  • Morris James LLP
  • USA
  • March 7 2016

Sleet, J. Claim construction opinion issues regarding three terms from four patents. A Markman hearing took place on February 5, 2016. The disputed

FDA’s animal-drug rule amendment allows more progesterone residues in meat
  • Shook Hardy & Bacon LLP
  • USA
  • September 23 2011

Asserting that its technical animal-drug-regulation amendment is not subject to congressional review, the Food and Drug Administration (FDA) has issued a final rule that increases the allowable residues of progesterone in edible tissues of cattle and sheep to reflect revised daily consumption values in a 1994 guidance document.

More hospitals to be scrutinized for Medicare coverage of implantable cardioverter defribillators (ICDs)
  • King & Spalding LLP
  • USA
  • March 7 2011

As previously reported in Health Headlines, the United States Department of Justice (DOJ) a year ago initiated a civil investigation into hospital billing for ICDs that has continued to broaden over time, sweeping hundreds of hospitals into its net.

Cases T-49307, T-2608 and T- 2708: GlaxoSmithKline Spa, Laboratórios Wellcome de Portugal, Lda and the Wellcome Foundation Ltd v OHIM
  • Squire Patton Boggs
  • European Union
  • November 2 2009

The Court of First Instance has rejected a combined appeal by GlaxoSmithKline Spa (GlaxoSmithKline), Laboratórios Wellcome de Portugal, Lda (Wellcome) and The Wellcome Foundation Ltd (Wellcome Foundation) (together the Applicants), against decisions of the First Board of Appeal of OHIM for a declaration of invalidity of the Community Trade Mark FAMOXIN on the grounds there was no likelihood of confusion by the public with the earlier registered mark LANOXIN.

Robert D. Rhoad
  • Dechert LLP